Arsenic sulfide reverses cisplatin resistance in non-small cell lung cancer in vitro and in vivo through targeting PD-L1,Thoracic Cancer

当前位置： X-MOL 学术 › Thorac. Cancer › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Arsenic sulfide reverses cisplatin resistance in non-small cell lung cancer in vitro and in vivo through targeting PD-L1
Thoracic Cancer ( IF 2.3 ) Pub Date : 2021-09-01 , DOI: 10.1111/1759-7714.14136
Wei Tian _{1,

2} , Yinping Sun ₂ , Yuping Cheng ₂ , Xiao Ma ₃ , Weina Du ₄ , Wenna Shi ₅ , Qisen Guo ₆

Affiliation

Recent studies have found that programmed death ligand 1 (PD-L1) might be involved in chemotherapy resistance in non-small cell lung cancer (NSCLC). Arsenic sulfide (As₄S₄) has been recognized to have antitumor activities and enhance the cytotoxic effect of chemotherapy drugs. In this study, we aimed to verify the relationship between PD-L1 and cisplatin (DDP) resistance and identify whether As₄S₄ could reverse DDP resistance through targeting PD-L1 in NSCLC.

中文翻译：

硫化砷通过靶向PD-L1在体外和体内逆转非小细胞肺癌顺铂耐药

最近的研究发现，程序性死亡配体 1 (PD-L1) 可能与非小细胞肺癌 (NSCLC) 的化疗耐药有关。硫化砷（As ₄ S ₄）已被公认为具有抗肿瘤活性并增强化疗药物的细胞毒作用。在本研究中，我们旨在验证 PD-L1 与顺铂 (DDP) 耐药之间的关系，并确定 As ₄ S ₄是否可以通过靶向 NSCLC 中的 PD-L1 来逆转 DDP 耐药。

更新日期：2021-10-04

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文本刊介绍/投稿指南11